In what has so far been a huge day for health care news, we heard two important announcements in the type 2 diabetes space. Eli Lilly announced positive top-line data in its phase 3 trial of empagliflozin, which means the company will be retaining a potential diabetes blockbuster in its pipeline, something Eli Lilly needs as other big drugs are going over patent cliffs. Also, Johnson & Johnson is taking its drug in the same space, Invokana, before an FDA advisory committee on Thursday. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why these two drugs have such huge potential -- and what risks they face.
While you can certainly make huge gains in the pharmaceuticals space, there are other great plays in health care to make as well. The medical devices company Intuitive Surgical has been a longtime pick of Motley Fool superinvestor David Gardner, and has soared 1,002.94% since he recommended it in March 2005. David specializes in identifying game-changing companies like this long before others are keen to their disruptive potential, and he helps like-minded investors profit while Wall Street catches up. I invite you to learn more about how he picks his winners with a free, personal tour of his flagship service: Supernova. Inside, you'll discover the science behind his market-trouncing returns. Just click here now for instant access.
The article Big News for These 2 Diabetes Hopefuls originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.